Pace Diagnostics
Revolutionary point-of-care, affordable early detection Lung cancer and Tuberculosis diagnostics
https://wefunder.com/pace.diagnostics
Total raised on Wefunder: 127079
Total investors: 111
Quick facts
- Raised $2.5 million in seed investment; Won > $6 million in grants from US DoD, NIH, and NSF
- Huge markets and financial opportunities: 3.1 billion USD tuberculosis & 20 billion USD lung cancer diagnostics in 2022
- Our products - low cost, accurate, non-invasive, non-lab dependent lung cancer & tuberculosis tests
- Our CE Mark is targeted for 2023, allowing product distribution in EU countries; clear path to FDA clinical trials
- We have a portfolio of proprietary material, filed patents and licensed IPs
- Each year: 10 million new TB infections & 2 million deaths; 2.1 million new Lung Cancer cases & 2 million new deaths
- Our TB test is specifically developed to meet all WHO requirements for performance, cost and use
- British Biocell International (BBI) is our manufacturing partner
Team profiles
Pace Diagnostics
Revolutionary point-of-care, affordable early detection Lung cancer and Tuberculosis diagnostics
Last Funded December 2022
$127,079
raised from 111 investors
Pitch Video
Investor Panel